Pathophysiology of Cryptococcosis?
-
Cryptococcus neoformans is an encapsulated yeast. In 1894, Busse, a pathologist, first described the yeast in a paper he presented to the Greifswald Medical Society. Busse isolated the yeast from the tibia of a 31-year-old woman, noted its resistance to sodium hydroxide, and published the case report that same year. The following year, a surgeon named Buschke reported the same isolate from the same patient, thus establishing the early eponym of Busse-Buschke disease. This single case served to identify a new yeast and to prove its pathogenic potential.
-
@samik Of the more than 50 species that comprise the genus Cryptococcus, human disease is primarily associated with C neoformans and C gattii. Animal models provide much of the understanding of the pathogenesis and the host defense mechanisms involved in cryptococcal infections. Cryptococcosis is acquired in two routes; after exposure to C. neoformans in immunocompromised, causing rapidly progressive cryptococcosis; the second is with a phase of latency followed by reactivation and dissemination. The concept of latency has been validated in C. neoformans. The organism is primarily transmitted via the respiratory route, but not directly from human to human.